REGN Stock Analysis: Buy, Sell, or Hold?
REGN - Regeneron Pharmaceuticals Inc
$741.45
-7.99 (-1.07%)
▼
BUY
HIGH Confidence
Last Updated: January 30, 2026
Earnings: Jan 30, 2026
0d
Get Alerted When REGN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: REGN shows strong fundamentals and good volume confirmation. Solid entry point despite oversold pricing.
✅ BUY SIGNAL: REGN shows strong fundamentals and good volume confirmation. Solid entry point despite oversold pricing.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$703.43
Based on -2.0% avg growth
INTRINSIC VALUE TODAY
$436.78
Trading above fair value
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 19.7x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: REGN is currently trading at $741.45, which is considered oversold relative to its 30-day fair value range of $747.63 to $786.95. The stock's valuation (Forward PE: 18.9) is in line with its historical norms (19.7). Remarkably, the market is currently pricing in an annual earnings decline of 1.4% over the next few years. This pessimistic expectation contrasts with the company's recent 18.0% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, REGN is in a strong uptrend. Immediate support is located at $718.38, while resistance sits at $776.25.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $831.38 (+10.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, REGN is in a strong uptrend. Immediate support is located at $718.38, while resistance sits at $776.25.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $831.38 (+10.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$747.63 -
$786.95
Company Quality Score
52/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.1%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading below Wall St target ($831.38)
Fair Price Analysis
30-Day Fair Range
$747.63 -
$786.95
Current vs Fair Value
OVERSOLD
Support & Resistance Levels
Support Level
$718.38
Resistance Level
$776.25
Current Trend
Strong Uptrend
Fundamental Context
Forward P/E (Next Year Est.)
18.88
Wall Street Target
$831.38
(+10.9%)
Revenue Growth (YoY)
0.9%
Earnings Growth (YoY)
18.0%
Profit Margin
32.1%
Valuation Discount vs History
-1.4% cheaper
PE vs Historical
18.9 vs 19.7
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-1.4%
(market-implied from PE analysis)
1-Year Target
$738.95
(-1%)
2-Year Target
$728.60
(-3%)
3-Year Target
$718.40
(-4%)
3-Yr Target (if PE normalizes)
(PE: 19→20)
$749.48
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.3, Growth: -8.0%)
$689.99
(+-8%)
Base:
(SPY PE: 18.9, Growth: -8.0%)
$584.27
(-22%)
Bear:
(PE: 16.1, Growth: -8.0%)
$496.63
(-34%)
📈
Valuation based on Current Earnings
Trailing PE: 18.02 | Current EPS (TTM): $41.69
Bull Case
$786.57
(+6%)
Analyst growth -4.8%, PE expands to 19.8
Base Case
$715.07
(-4%)
Market implied -4.8%, PE stable at 18.0
Bear Case
$510.77
(-31%)
Severe decline -20.0%, PE contracts to 15.3
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 18.9 to 19.7
Stabilization Target:
$781.86
(+4.3%)
PE Expansion Potential:
+4.3%
Last updated: January 30, 2026 7:50 PM ET
Data refreshes hourly during market hours. Next update: 8:50 PM
Data refreshes hourly during market hours. Next update: 8:50 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is REGN showing a specific setup today?
Insider Activity (6 Months)
2
Buys
1
Sells
+
Net
NEUTRAL
Recent Transactions
Ro Khanna
SELL
2025-09-29
Ro Khanna
BUY
2025-08-26
Ro Khanna
BUY
2025-08-04
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$500 | 62 BUY |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$56 | 59 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$210 | 57 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$64 | 55 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$102 | 62 BUY |
Advanced REGN Option Strategies
Professional options setups generated by AI based on today's REGN price and gamma walls.
